Inhibiting the mitochondrial pyruvate carrier does not ameliorate synucleinopathy in the absence of inflammation or metabolic deficits

Inhibiting the mitochondrial pyruvate carrier does not ameliorate synucleinopathy in the absence of inflammation or metabolic deficits

Epidemiological studies suggest a link between type-2 diabetes and Parkinson’s disease (PD) risk. Treatment of type-2 diabetes with insulin sensitizing drugs lowers the risk of PD. We previously showed that the insulin sensitizing drug, MSDC-0160, ameliorates pathogenesis in some animal models of PD...

Full description

Bibliographic Details
Main Authors: Wouter Peelaerts, Liza Bergkvist, Sonia George, Michaela Johnson, Lindsay Meyerdirk, Emily Schulz, Jennifer A. Steiner, Zachary Madaj, Jiyan Ma, Katelyn Becker, K. Peter R. Nilsson, Jerry R. Colca, Patrik Brundin
Format: Article
Language:English
Published: University of Münster / Open Journals System 2020-11-01
Series:Free Neuropathology
Subjects:
parkinson's disease
synuclein
neurodegeneration
metabolism
synucleinopathy
Online Access:https://www.uni-muenster.de/Ejournals/index.php/fnp/article/view/3049

Internet

https://www.uni-muenster.de/Ejournals/index.php/fnp/article/view/3049

Similar Items